Mesa, AZ
Peptide Therapy clinics in Mesa
Mesa has a growing East Valley market with a mix of retirees and young families, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across Dana Park, Las Sendas, and the Eastmark area range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the Banner Desert, Mountain Vista, and Dignity Health Chandler network. The scene here skews toward DO-led and NP-led clinics targeting a mixed-age Valley demographic. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable Mesa clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Precision Integrative Specialists & Oncology
- PRP Therapy
- Ozone Therapy
- IV Therapy
- Hyperbaric Oxygen Therapy (HBOT)
- Ketamine Therapy
Optimum Weight Loss
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- Peptide Therapy
- Erectile Dysfunction (ED) Treatment
Family Allergy Clinic and Wellness Center
- NAD IV Therapy
- Vitamin IV Therapy
- PRP Therapy
- IV Therapy
- IV Hydration
Vis Vitalis Regenerative Medicine
- PRP Therapy
- Shockwave Therapy
- Ozone Therapy
- IV Therapy
- Acne Treatment
Regulatory context
A note on Arizona's peptide therapy rules.
Most research peptides sold in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin are FDA-approved for specific indications. In 2023 and 2024, the FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list, which effectively restricts 503A compounding pharmacies from sourcing those ingredients. Section 503A governs traditional patient-specific compounding; Section 503B covers FDA-registered outsourcing facilities held to cGMP standards.
-
Arizona Revised Statutes Title 32 Chapter 18 (Pharmacy)
Governs compounding, pharmacy licensure, and drug distribution under the Arizona State Board of Pharmacy. -
Arizona Revised Statutes Title 32 Chapter 14 (Naturopathic Physicians)
Grants licensed naturopathic physicians prescriptive authority, including for compounded preparations within scope. -
Arizona Revised Statutes Title 32 Chapter 13 (Medicine and Surgery)
Regulates MD practice and delegation of peptide administration to qualified staff.
The Arizona State Board of Pharmacy inspects compounding facilities under USP 795 (non-sterile) and USP 797 (sterile) standards. The Board has issued disciplinary actions against pharmacies for sourcing non-compliant bulk ingredients and for sterile compounding deficiencies. Non-resident pharmacies shipping peptides into Arizona must hold a non-resident permit. Clinics sourcing from pharmacies outside the state should verify the pharmacy holds a current Arizona non-resident license.